The role of interferon-β in the treatment of multiple sclerosis and experimental autoimmune encephalomyelitis - in the perspective of inflammasomes

Immunology

Volumn 139, Issue 1, 2013, Pages 11-18

  Inoue, Makoto ^a   Shinohara, Mari L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cell migration; Chemotaxis; Experimental autoimmune encephalomyelitis; Interferon ; Multiple sclerosis; NLRP3 inflammasome

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMYLOID BETA PROTEIN; BETA INTERFERON; CASPASE 11; CATHEPSIN B; CHEMOKINE RECEPTOR CXCR6; CHOLERA TOXIN B SUBUNIT; CRYOPYRIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; P2X7R ANTAGONISTS; PATTERN RECOGNITION RECEPTOR; PURINE; PURINERGIC P2X RECEPTOR ANTAGONIST; PURINERGIC P2X7 RECEPTOR; SUPPRESSOR OF CYTOKINE SIGNALING 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIC ACID; VERY LATE ACTIVATION ANTIGEN 4;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ALLERGIC ENCEPHALOMYELITIS; AMYLOID PLAQUE; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; AUTOIMMUNITY; AUTOINFLAMMATORY DISEASE; BLOOD BRAIN BARRIER; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CELIAC DISEASE; CELL DIVISION; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CINCA SYNDROME; CROHN DISEASE; DEMYELINATING DISEASE; DENDRITIC CELL; DISEASE COURSE; DISEASE MODEL; ESCHERICHIA COLI; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENETIC RECOMBINATION; HELPER CELL; HUMAN; IMMUNOCOMPETENT CELL; IN VIVO STUDY; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; KNOCKOUT MOUSE; MACROPHAGE; MUCKLE WELLS SYNDROME; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NECROSIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; TH17 CELL; ULCERATIVE COLITIS;

ANIMALS; AUTOIMMUNITY; CARRIER PROTEINS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; INFLAMMASOMES; INTERFERON-BETA; MULTIPLE SCLEROSIS;

EID: 84876049501     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12081     Document Type: Article

References (84)

1. Kepp O, Galluzzi L, Zitvogel L, Kroemer G. Pyroptosis - a cell death modality of its kind? Eur J Immunol 2010; 40:627-30.
2. Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol 2009; 7:99-109.
3. Fink SL, Cookson BT. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun 2005; 73:1907-16.
4. Lamkanfi, M Emerging inflammasome effector mechanisms. Nat Rev Immunol 2011; 11:213-20.
5. Mariathasan S, Weiss DS, Newton K et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006; 440:228-32.
6. Gross O, Poeck H, Bscheider M et al. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature 2009; 459:433-6.
7. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237-41.
8. Halle A, Hornung V, Petzold GC et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat Immunol 2008; 9:857-65.
9. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008; 320:674-7.
10. Hornung V, Bauernfeind F, Halle A et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008; 9:847-56.
11. Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 2010; 10:210-5.
12. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140:821-32.
13. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004; 20:319-25.
14. Allen IC, Scull MA, Moore CB et al. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 2009; 30:556-65.
15. Fiorentino L, Stehlik C, Oliveira V, Ariza ME, Godzik A, Reed JC. A novel PAAD-containing protein that modulates NF-κB induction by cytokines tumor necrosis factor-α and interleukin-1β. J Biol Chem 2002; 277:35333-40.
16. Ye Z, Lich JD, Moore CB, Duncan JA, Williams KL, Ting JP. ATP binding by monarch-1/NLRP12 is critical for its inhibitory function. Mol Cell Biol 2008; 28:1841-50.
17. Allen IC, Wilson JE, Schneider M et al. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-κB signaling. Immunity 2012; 36:742-54.
18. Kayagaki N, Warming S, Lamkanfi M et al. Non-canonical inflammasome activation targets caspase-11. Nature 2011; 479:117-21.
19. Arostegui JI, Aldea A, Modesto C et al. Clinical and genetic heterogeneity among Spanish patients with recurrent autoinflammatory syndromes associated with the CIAS1/PYPAF1/NALP3 gene. Arthritis Rheum 2004; 50:4045-50.
20. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001; 29:301-5.
21. Dode C, Le Du N, Cuisset L et al. New mutations of CIAS1 that are responsible for Muckle-Wells syndrome and familial cold urticaria: a novel mutation underlies both syndromes. Am J Hum Genet 2002; 70:1498-506.
22. Feldmann J, Prieur AM, Quartier P et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 2002; 71:198-203.
23. Meng G, Zhang F, Fuss I, Kitani A, Strober W. A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity 2009; 30:860-74.
24. Pontillo A, Girardelli M, Kamada AJ, Pancotto JA, Donadi EA, Crovella S, Sandrin-Garcia P. Polymorphisms in inflammasome genes are involved in the predisposition to systemic lupus erythematosus. Autoimmunity 2012; 45:271-8.
25. Pontillo A, Brandao L, Guimaraes R, Segat L, Araujo J, Crovella S. Two SNPs in NLRP3 gene are involved in the predisposition to type-1 diabetes and celiac disease in a pediatric population from northeast Brazil. Autoimmunity 2010; 43:583-9.
26. Villani AC, Lemire M, Louis E et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. PLoS ONE 2009; 4:e7154.
27. Glinskii AB, Ma J, Ma S, Grant D, Lim CU, Sell S, Glinsky GV. Identification of intergenic trans-regulatory RNAs containing a disease-linked SNP sequence and targeting cell cycle progression/differentiation pathways in multiple common human disorders. Cell Cycle 2009; 8:3925-42.
28. Sui J, Li H, Fang Y et al. NLRP1 gene polymorphism influences gene transcription and is a risk factor for rheumatoid arthritis in Han Chinese. Arthritis Rheum 2012; 64:647-54.
29. Veeranki S, Choubey D. Systemic lupus erythematosus and increased risk to develop B cell malignancies: role of the p200-family proteins. Immunol Lett 2010; 133:1-5.
30. Furlan R, Filippi M, Bergami A et al. Peripheral levels of caspase-1 mRNA correlate with disease activity in patients with multiple sclerosis; a preliminary study. J Neurol Neurosurg Psychiatry 1999; 67:785-8.
31. Ming X, Li W, Maeda Y, Blumberg B, Raval S, Cook SD, Dowling PC. Caspase-1 expression in multiple sclerosis plaques and cultured glial cells. J Neurol Sci 2002; 197:9-18.
32. Huang WX, Huang P, Hillert J. Increased expression of caspase-1 and interleukin-18 in peripheral blood mononuclear cells in patients with multiple sclerosis. Mult Scler 2004; 10:482-7.
33. de Jong BA, Huizinga TW, Bollen EL et al. Production of IL-1β and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis. J Neuroimmunol 2002; 126:172-9.
34. Amorini AM, Petzold A, Tavazzi B et al. Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin Biochem 2009; 42:1001-6.
35. Liu B, Shen Y, Xiao K, Tang Y, Cen L, Wei J. Serum uric acid levels in patients with multiple sclerosis: a meta-analysis. Neurol Res 2012; 34:163-71.
36. Bever CT Jr, Panitch HS, Johnson KP. Increased cathepsin B activity in peripheral blood mononuclear cells of multiple sclerosis patients. Neurology 1994; 44:745-8.
37. Bever CT Jr, Garver DW. Increased cathepsin B activity in multiple sclerosis brain. J Neurol Sci 1995; 131:71-3.
38. Matute C, Torre I, Perez-Cerda F et al. P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J Neurosci 2007; 27:9525-33.
39. Vallejo-Illarramendi A, Domercq M, Perez-Cerda F, Ravid R, Matute C. Increased expression and function of glutamate transporters in multiple sclerosis. Neurobiol Dis 2006; 21:154-64.
40. Oyanguren-Desez O, Rodriguez-Antiguedad A, Villoslada P, Domercq M, Alberdi E, Matute C. Gain-of-function of P2X7 receptor gene variants in multiple sclerosis. Cell Calcium 2011; 50:468-72.
41. Gris D, Ye Z, Iocca HA et al. NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J Immunol 2010; 185:974-81.
42. Jha S, Srivastava SY, Brickey WJ et al. The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18. J Neurosci 2010; 30:15811-20.
43. Inoue M, Williams KL, Gunn MD, Shinohara ML. NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2012; 109:10480-5.
44. Inoue M, Williams KL, Oliver T, Vandenabeele P, Rajan JV, Miao EA, Shinohara ML. Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome. Sci Signal 2012; 5:ra38.
45. Furlan R, Martino G, Galbiati F et al. Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J Immunol 1999; 163:2403-9.
46. Ahmed Z, Doward AI, Pryce G et al. A role for caspase-1 and -3 in the pathology of experimental allergic encephalomyelitis: inflammation versus degeneration. Am J Pathol 2002; 161:1577-86.
47. Soulika AM, Lee E, McCauley E, Miers L, Bannerman P, Pleasure D. Initiation and progression of axonopathy in experimental autoimmune encephalomyelitis. J Neurosci 2009; 29:14965-79.
48. Alvarez JI, Dodelet-Devillers A, Kebir H et al. The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science 2011; 334:1727-31.
49. Ferrari CC, Depino AM, Prada F et al. Reversible demyelination, blood-brain barrier breakdown, and pronounced neutrophil recruitment induced by chronic IL-1 expression in the brain. Am J Pathol 2004; 165:1827-37.
50. Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 2006; 203:1685-91.
51. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH. Interleukin-1 and IL-23 induce innate IL-17 production from γδ T cells, amplifying Th17 responses and autoimmunity. Immunity 2009; 31:331-41.
52. Lalor SJ, Dungan LS, Sutton CE, Basdeo SA, Fletcher JM, Mills KH. Caspase-1-processed cytokines IL-1β and IL-18 promote IL-17 production by γδ and CD4 T cells that mediate autoimmunity. J Immunol 2011; 186:5738-48.
53. Matejuk A, Vandenbark AA, Burrows GG, Bebo BF Jr, Offner H. Reduced chemokine and chemokine receptor expression in spinal cords of TCR BV8S2 transgenic mice protected against experimental autoimmune encephalomyelitis with BV8S2 protein. J Immunol 2000; 164:3924-31.
54. Izikson L, Klein RS, Charo IF, Weiner HL, Luster AD. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med 2000; 192:1075-80.
55. Kim JV, Jiang N, Tadokoro CE, Liu L, Ransohoff RM, Lafaille JJ, Dustin ML. Two-photon laser scanning microscopy imaging of intact spinal cord and cerebral cortex reveals requirement for CXCR6 and neuroinflammation in immune cell infiltration of cortical injury sites. J Immunol Methods 2010; 352:89-100.
56. Chabas D, Baranzini SE, Mitchell D et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001; 294:1731-5.
57. Sorensen TL, Sellebjerg F. Distinct chemokine receptor and cytokine expression profile in secondary progressive MS. Neurology 2001; 57:1371-6.
58. Misu T, Onodera H, Fujihara K et al. Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling. J Neuroimmunol 2001; 114:207-12.
59. Shinohara ML, Jansson M, Hwang ES, Werneck MB, Glimcher LH, Cantor H. T-bet-dependent expression of osteopontin contributes to T cell polarization. Proc Natl Acad Sci USA 2005; 102:17101-6.
60. Jansson M, Panoutsakopoulou V, Baker J, Klein L, Cantor H. Cutting edge: attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. J Immunol 2002; 168:2096-9.
61. Hur EM, Youssef S, Haws ME, Zhang SY, Sobel RA, Steinman L. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol 2007; 8:74-83.
62. Shinohara ML, Kim JH, Garcia VA, Cantor H. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity 2008; 29:68-78.
63. Guarda G, Braun M, Staehli F et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011; 34:213-23.
64. Hernandez-Cuellar E, Tsuchiya K, Hara H et al. Cutting edge: nitric oxide inhibits the NLRP3 inflammasome. J Immunol 2012; 189:5113-7.
65. Guo B, Chang EY, Cheng G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest 2008; 118:1680-90.
66. Prinz M, Schmidt H, Mildner A et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 2008; 28:675-86.
67. Ramgolam VS, Markovic-Plese S. Interferon-β inhibits Th17 cell differentiation in patients with multiple sclerosis. Endocr Metab Immune Disord Drug Targets 2010; 10:161-7.
68. Ramgolam VS, Sha Y, Jin J, Zhang X, Markovic-Plese S. IFN-β inhibits human Th17 cell differentiation. J Immunol 2009; 183:5418-27.
69. + cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells. Mol Immunol 2008; 45:4008-19.
70. Pirhonen J, Siren J, Julkunen I, Matikainen S. IFN-α regulates Toll-like receptor-mediated IL-27 gene expression in human macrophages. J Leukoc Biol 2007; 82:1185-92.
71. Yong VW, Chabot S, Stuve O, Williams G. Interferon β in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998; 51:682-9.
72. Sharief MK, Semra YK, Seidi OA, Zoukos Y. Interferon-β therapy downregulates the anti-apoptosis protein FLIP in T cells from patients with multiple sclerosis. J Neuroimmunol 2001; 120:199-207.
73. Arbour N, Rastikerdar E, McCrea E, Lapierre Y, Dorr J, Bar-Or A, Antel JP. Upregulation of TRAIL expression on human T lymphocytes by interferon β and glatiramer acetate. Mult Scler 2005; 11:652-7.
74. + regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis. J Neuroimmunol 2012; 242:39-46.
75. Muraro PA, Leist T, Bielekova B, McFarland HF. VLA-4/CD49d downregulated on primed T lymphocytes during interferon-β therapy in multiple sclerosis. J Neuroimmunol 2000; 111:186-94.
76. Boz C, Ozmenoglu M, Velioglu S, Kilinc K, Orem A, Alioglu Z, Altunayoglu V. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon β. Clin Neurol Neurosurg 2006; 108:124-8.
77. Comabella M, Rio J, Espejo C et al. Changes in matrix metalloproteinases and their inhibitors during interferon-β treatment in multiple sclerosis. Clin Immunol 2009; 130:145-50.
78. Shaw PJ, Lukens JR, Burns S, Chi H, McGargill MA, Kanneganti TD. Cutting edge: critical role for PYCARD/ASC in the development of experimental autoimmune encephalomyelitis. J Immunol 2010; 184:4610-4.
79. Hanamsagar R, Hanke ML, Kielian T. Toll-like receptor (TLR) and inflammasome actions in the central nervous system. Trends Immunol 2012; 33:333-42.
80. Arnason BG. Immunologic therapy of multiple sclerosis. Annu Rev Med 1999; 50:291-302.
81. Axtell RC, de Jong BA, Boniface K et al. T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010; 16:406-12.
82. Kantarci OH, Atkinson EJ, Hebrink DD, McMurray CT & Weinshenker BG. Association of two variants in IL-1beta and IL-1 receptor antagonist genes with multiple sclerosis. J Neuroimmunol 2000; 106:220-7.
83. Badovinac V, Mostarica-Stojkovic M, Dinarello CA & Stosic-Grujicic S. Interleukin-1 receptor antagonist suppresses experimental autoimmune encephalomyelitis (EAE) in rats by influencing the activation and proliferation of encephalitogenic cells. J Neuroimmunol 1998; 85:87-95.
84. Shi FD, Takeda K, Akira S, Sarvetnick N & Ljunggren HG. IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-gamma by NK cells. J Immunol 2000; 165:3099-3104.